《中国医疗器械企业全球化发展——热门市场概览与制胜因素》英-德勤-52页_3mb

Summary of Chinese Medical Device Companies Going Global

Introduction

The report "Insights into Chinese Medical Device Companies Going Global" highlights the imperative for Chinese medical device firms to expand overseas due to domestic challenges, such as severe competition in low-value consumables and weak R&D capabilities. Overseas markets offer significant opportunities, including large incremental segments, price advantages due to higher global pricing, and enhanced brand recognition post-COVID-19. Deloitte collaborated with regional teams to analyze seven popular target markets: United States, Germany, France, United Kingdom, Brazil, Malaysia, and Singapore, providing insights into market entry strategies, regulatory requirements, and key success factors.

Challenges in Domestic Market and Opportunities Abroad

Chinese companies face intense homogenization in low-value consumables and rely heavily on imports for high-end devices like diagnostic imaging. In contrast, overseas markets provide growth potential, higher price stability, and cost-performance advantages. For instance, U.S. device prices are significantly higher (e.g., coronary stents up to 6-10 times more expensive in the U.S.), fostering opportunities for Chinese firms with 20-30% average international revenue, a gap compared to global leaders.

Popular Target Markets Overview

• United States: Largest market with strong R&D, but challenges include FDA regulations, reimbursement complexities, and competition.
• Germany: Mature market with high medical device exports; opportunities lie in imaging and orthopedics, but require local operations and compliance with BfArM regulations.
• France: Pluralistic health insurance system drives demand for high-value devices; key growth areas include oral health and oncology, with CEPS and ANSM regulating prices and access.
• United Kingdom: Aging population boosts healthcare demand; strategies involve acquisitions and greenfield investment, navigating post-Brexit regulatory changes.
• Brazil: Fragmented healthcare system with SUS dominance; price controls and import dependencies pose challenges, but strategic partnerships can expand market share.
• Malaysia: Focus on high-end devices; competition requires navigating MDA regulations and localization efforts.
• Singapore: High-reliance on imports; advantage in trade hub status, but clinical trial requirements and labor costs present hurdles.

Common themes include regulatory hurdles, supply chain management, and cultural integration.

Key Success Factors

Success hinges on strategic positioning, such as creating differential advantages and defining key success metrics. Stable operations involve building robust supply chains and organizational structures, while functional support includes talent ecosystem cultivation and local integration. Companies should conduct thorough market research, optimize operations, manage risks (e.g., geopolitical, supply chain), and ensure digital capabilities for global data sharing. Implementing a phased framework with clear performance standards enhances execution.

Conclusion

Global expansion is vital for Chinese medical device companies to overcome domestic limitations. By leveraging strategies like targeted market entry, innovation, and compliance, firms can capitalize on overseas opportunities despite challenges, driving sustainable growth and international competitiveness.